The New Technology Could Bring Benefits to Cancer Patients if the Tumor is Identified

Ms. Gurli, a 68-year-old Danish anti-cancer celebrity

“To know others having cancer is one thing, but to know yourself having cancer is another thing. My world was almost collapsed when I got to know my diagnosis.” Ms. Gurli, a retired Danish teacher said when she was sharing her experience of “living with cancer”. It~s hard to tell that she has been a 68-year-old cancer patient from her energetic demeanor. In 2008, her Danish doctor claimed that “she only had three to four months to live whatever treatments she would receive”. What it is that has made her such an active and humorous person 8 years later.

In the morning of March 16, 2016, Guangzhou Fuda Cancer Hospital held a special experience sharing meeting, on which the cancer patient Ms. Gurli, the 100th patient who has underwent NanoKnife illustrated to the attendants the success of NanoKnife with her own experience. It is known that conventional resection operation would inflict great physical trauma to cancer patient; it makes cancer patients even more painful to undergo radiotherapy and chemotherapy. Moreover, resection operation would often inflict irreversible damage to normal tissues, blood vessels and nerve system in particular. The physical trauma and damage would adversely affect postoperative recovery and the living quality of patient. Hence, in the face of treatment, cancer patients have more fears to the operative wound and the trauma that might be caused by resection operation. Fortunately, we are pleased to see the application of a latest treatment modality for cancer that is NanoKnife. According to Prof. Niu, Executive President of Guangzhou Fuda Cancer Hospital, during the procedure of NanoKnife, high electric-field and ultrashort pulses are given to destroy lipid bilayer structure of cancer cell membrane and form numerous irreversible nano-sized pores in the cell membrane. Cell membrane permeability will be changed to allow molecules of different sizes free access to cells, which will lead to cell death. Apoptotic tumor cells will be consumed by immune cells as their antigens are exposed. The zone where tumor was located will be replaced by normal cells and resume normal function gradually. In short, NanoKnife is a mini-invasive, harmless or low harm, precise and effective method for tumor inactivation. The most distinctive feature of NanoKnife is that it can preserve the normal tissues and structures in the targeted area in a non-invasive way so as to create favorable conditions for the blood vessels, nerve tissues in the ablated area to restore their normal function. Ms. Gurli underwent NanoKnife for the multiple neuroendocrine neoplasms in liver on March 8, 2016. She was full of spirit and energy and was able to walk and talk like a normal person when we met her at the experience sharing meeting. Such a fast postoperative recovery can never be seen in traditional resection operation.

Dr. Lu Mingying, the Rank Prize winner and Chinese scientist shared with the attendants her successful treatment experience

Another special patient also presented at the experience sharing meeting. She is Dr. Lu Mingying, the Rank Prize winner and Chinese scientist. She learned of NanoKnife on the internet. She noted, “I searched on the internet with NanoKnife as the keyword and found Guangzhou Fuda Cancer Hospital in the end. I made several phone calls to FUDA and learned that FUDA has completed over 70 cases of NanoKnife at that time. I believe that NanoKnife has been well developed at FUDA and I made the decision to FUDA to receive NanoKnife.” Prof. Niu said, “She could not walk due to intense abdominal pain and abdominal distension upon admission.” Dr. Lu Mingying underwent NanoKnife at FUDA on February 2, 2016. She had her symptoms alleviated significantly and was able to walk on February 6. It is reported that NanoKnife is applicable to liver cancer, lung cancer, kidney cancer, prostate cancer and other solid cancers. It has distinctive advantage in treating tumors that is close to hepatic hilus, gallbladder bile duct, pancreas, and ureter. Moreover, over half cases of NanoKnife in China are completed at Fuda Cancer Hospital.


Xu Kecheng, Chief President of Guangzhou Fuda Cancer Hospital noted that over the past ten years, Fuda Cancer Hospital has been committing to treat advanced cancer--a difficult medical problem in the world with “3C+P” treatment model dominated by cryosurgical ablation (CSA), cancer microvascular intervention (CMI) and combined immunotherapy for cancer (CIC) with an aim of prolonging patients~ life and improving their quality of life. FUDA has been leading the world in terms of the number of cases and types of cancer that CSA has treated; FUDA has also made breakthrough achievements in treating central lung cancer, great hepatic carcinoma, and pancreatic cancer with CSA, which has won several awards for FUDA at home and abroad. In June, 2015, FUDA introduced NanoKnife equipment from America and carried out the first NanoKnife on pancreatic cancer in mainland China on July 2, 2015. As of now, FUDA has completed 100 cases of NanoKnife, the number of which ranks the first in China.


On the same day, Guangzhou Fuda Cancer Hospital and BGI Group signed a strategic alliance agreement. FUDA-BGI strategic alliance allows experts on both sides to carry out concrete discussion on the cooperation vision and feasibility of the building and application of tumor sample data base, tumor detection at molecular level and the screening and early warning of high risk group by combining cancer high incidence scene and high-throughput sequencing.